文献速递血液净化与透析水电解质与酸碱

EVOLVE试验中西那卡塞治疗患者低钙血症的发生率、预测因素及治疗后果

Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial.
PubMed 文献 · Kidney Int · 2018-03-07

该研究为EVOLVE随机双盲安慰剂对照试验的事后分析,评估透析患者使用西那卡塞后低钙血症的发生率、预测因素及治疗后果。结果显示西那卡塞组58.3%患者出现至少一次低钙血症,显著高于安慰剂组的14.9%,严重低钙血症发生率分别为18.4%和4.4%。低钙血症多无症状且自限,严重低钙血症与基线甲状旁腺激素水平较高、校正血钙较低等因素相关。

要点

  • 西那卡塞起始治疗后16周内低钙血症发生率高达58.3%,多为无症状且自限。
  • 严重低钙血症与基线甲状旁腺激素升高、校正血钙降低、碱性磷酸酶升高相关。
  • 多数低钙血症在14天内自行缓解,干预措施以增加活性维生素D剂量最常见。

核心结论

  • 西那卡塞起始治疗后低钙血症常见,其发生与继发性甲状旁腺功能亢进的严重程度相关,但多无症状且自限。

研究设计与样本

  • EVOLVE随机双盲安慰剂对照试验的事后分析,西那卡塞组1938例,安慰剂组1923例。

主要发现

  • 西那卡塞组58.3%患者出现至少一次低钙血症,安慰剂组为14.9%。
  • 西那卡塞组严重低钙血症(血钙低于7.5 mg/dL)占18.4%,安慰剂组占4.4%。
  • 严重低钙血症与较高基线血浆甲状旁腺激素、较低校正总血钙、较高血清碱性磷酸酶、地区(拉丁美洲和俄罗斯风险高于美国)及较高体重指数相关。
  • 首次低钙血症发作前西那卡塞中位剂量为54-58 mg/天,三种低钙血症分类中相似。
  • 多数患者低钙血症在14天内自行缓解,无需调整背景治疗;接受干预者中最常见的是增加活性维生素D甾醇剂量。

关键数值与推荐

  • 低钙血症分类:轻度(总血钙8.0-8.39 mg/dL)、中度(7.5-7.99 mg/dL)、严重(低于7.5 mg/dL)。

临床怎么用

  • 透析患者使用西那卡塞时应监测血钙,尤其对于基线甲状旁腺激素高、血钙低、碱性磷酸酶高及高体重指数者。
  • 多数低钙血症无症状且自限,严重者可通过增加活性维生素D剂量处理。

局限性

  • 本研究为事后分析,可能存在混杂因素。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The calcimimetic cinacalcet is used to treat secondary hyperparathyroidism in patients receiving dialysis, and asymptomatic hypocalcemia is often observed following its initiation. Here we investigated the incidence, predictors and therapeutic consequences of hypocalcemia by a post hoc analysis of the randomized, double-blind, placebo-controlled EValuation Of Cinacalcet Hydrochloride Therapy to Lower CardioVascular Events (EVOLVE) trial. Hypocalcemia was classified as mild (total serum calcium 8.0-8.39 mg/dL), moderate (7.5-7.99 mg/dL) or severe (under 7.5 mg/dL). At least one episode of hypocalcemia developed within 16 weeks after the first administered dose among 58.3% of 1938 patients randomized to cinacalcet versus 14.9% of 1923 patients randomized to placebo. Hypocalcemia in the cinacalcet group was severe in 18.4% of the patients versus 4.4% in the placebo group. Severe hypocalcemia following administration of cinacalcet was associated with higher baseline plasma parathyroid hormone, lower corrected total serum calcium, higher serum alkaline phosphatase, geographic region (patients from Latin America and Russia had a higher risk relative to the United States) and higher body mass index. The median cinacalcet dose immediately prior to the first hypocalcemic episode was 54-58 mg/day and similar in the three hypocalcemia categories. In the majority of patients, hypocalcemia resolved spontaneously within 14 days without modification of background therapy. Among patients who received an intervention, the most common was an increase in the active vitamin D sterol dose. Thus, the occurrence of hypocalcemia is frequent following initiation of cinacalcet and the likelihood of developing hypocalcemia was related to the severity of secondary hyperparathyroidism. Hypocalcemia was generally asymptomatic and self-limited.

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Floege J, Tsirtsonis K, Iles J, et al. Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial. Kidney Int. 2018. PMID: 29525393. doi:10.1016/j.kint.2017.12.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。